logo-loader

Shares of Compugen gain on US$200mln licensing deal for cancer treatments

Last updated: 13:43 03 Apr 2018 BST, First published: 16:43 03 Apr 2018 BST

An AstraZeneca production plant
The stock gained 8.2% in pre-market trading

Compugen Ltd., (NASDAQ:CGEN) an Israeli drugmaker, rose in trading after yesterday agreeing to an exclusive licensing deal worth as much as US$200mln with a division of AstraZeneca PLC (LON:AZN) to develop antibody products aimed at treating cancer.

The stock gained 2.4% to US$4.35, giving the company a market value of about US$222mln.

Monetizes specific scientific advances

The AstraZeneca unit, MedImmune, will provide an upfront payment of US$10mln to Compugen, giving it the right to “create multiple products” and be “solely responsible for all research, development and commercial activities,” Compugen said in a statement on its website.

“This licensing deal allows us to monetize specific scientific advances in our programs,” Anat Cohen-Dayag, Compugen’s chief executive officer, said in the statement.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

42 minutes ago